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Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by excess fat accumulation in 
the hepatocytes (nonalcoholic fatty liver, NAFL); in up to 40% of individuals, there are additional 
findings of portal and lobular inflammation, and hepatocyte injury (nonalcoholic steatohepatitis, 
NASH). A small percent of patients will develop progressive fibrosis and cirrhosis. Hepatocellular 
carcinoma and cardiovascular complications are life-threatening co-morbidities of both NAFL and 
NASH. NAFLD is closely associated with insulin resistance; obesity and metabolic syndrome are 
common underlying factors. As a consequence, the prevalence of NAFLD is estimated to be 10-40% 
in adults worldwide, and it is the most common liver disease in children and adolescents in 
developed countries. Mechanistic insights into fat accumulation, subsequent hepatocyte injury, the 
role of the immune system and fibrosis as well as the role of the gut microbiome are unfolding, and 
genetic and epigenetic factors might explain the considerable inter-individual variation in disease 
phenotype, severity and progression. To date, no effective medical interventions exist that 
completely reverse the disease other than lifestyle changes, dietary alterations and possibly, 
bariatric surgery. However, several strategies targeting pathophysiological processes such as 
oversupply of fatty acids to the liver, cell injury and inflammation are currently under investigation. 
Diagnosis of NAFLD, and detecting the lesions of NASH, still depend on the gold-standard but 
invasive liver biopsy. Several non-invasive strategies are being validated to replace or complement 
biopsies, especially for follow-up monitoring. 
   
  
2 
 
 
Nonalcoholic fatty liver disease (NAFLD) has been accepted as a bona fide disease entity in the late 
20th century. The disorder is characterized by accumulation of fat (in the form of triglycerides) in 
hepatocytes (>5% fat content in the liver; referred to as steatosis). In the presence of additional 
factors, described below, hepatocellular injury and death occur along with lobular and portal 
inflammation, and the disease is referred to as nonalcoholic steatohepatitis (NASH). Specific sites of 
collagen deposition and subsequent vascular remodelling, and ultimately cirrhosis may result.  
Several histological features of NAFLD and NASH are common to alcoholic fatty liver disease (AFLD), 
including steatosis, inflammation, hepatocellular ballooning (a type of hepatocyte cell injury), 
Mallory-Denk bodies (Mallory's hyaline) and fibrosis within the lobules. However, in contrast to the 
underlying exposure to excess alcohol that initiates and drives AFLD, patients with NAFLD are insulin 
resistant, usually obese, and are known not to consume excess alcohol. 1 Interestingly, whereas 
paediatric NAFLD shares similar metabolic triggers with NAFLD in adults, different patterns of 
histologic injury may be observed 2.  
Morbidity and mortality in patients with NAFLD are mainly caused by the cardiovascular 
complications, rather than by the liver disease itself3,4. Cirrhosis and hepatocellular carcinoma (HCC) 
are the most common liver-related causes of morbidity associated with NAFLD, followed by systemic 
infection5. That HCC is documented to occur in the absence of cirrhosis is a concern for clinical care6.  
Finally, the value of the liver biopsy as a diagnostic tool, although an invasive procedure, continues 
to be shown by large studies analysing the correlation between long-term outcomes with 
histopathological evaluation. Advanced fibrosis has been identified as the most significant histologic 
feature associated with poor outcomes in two studies5,7; inflammation is associated with initiation 
and progression of fibrosis8. Both in children and in adults, NASH-related cirrhosis is predicted to 
become the most common indication for liver transplant9. Several non-invasive diagnostic tools are 
currently being validated and show promise. 
In this Primer, we describe the worldwide prevalence of NAFLD in adults and children, highlight 
genomic and epigenomic changes associated with disease and its progression, as well as the 
molecular drivers of disease and elaborate on the advances in diagnosis and the current lack of 
management options and quality of life concerns. Avenues for progress are discussed. 
 
[H1] Epidemiology 
 
[H2] Adults 
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[H3] The United States and Europe. NAFLD is currently the most common cause of abnormal liver 
function tests in Western countries. According to population studies using ultrasonography or CT 
imaging, the prevalence of NAFLD is in the range 20–50% (Table 1).10–13 NAFLD prevalence varies 
markedly between ethnic groups. An urban population study in the United States using proton-
magnetic resonance spectroscopy (1H-MRS) showed that the prevalence of hepatic steatosis was 
45% in Hispanic, 33% in white, and 24% in black populations.14 These variations can be explained by 
differences in lifestyle, prevalence of metabolic syndrome and genetics, such as polymorphism of 
the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene, which encodes a lipase 
that mediates triacylglycerol hydrolysis in adipocytes. (Figure 1). NAFLD is strongly associated with 
metabolic disorders. Not surprisingly, fatty liver has been reported in 40–80% of patients with type 2 
diabetes mellitus and 30–90% of obese patients.15,16  
 
Since imaging can only detect fatty liver but not necroinflammation or fibrosis, the prevalence of 
NASH and the related liver fibrosis in the population is unclear. Histological analyses suggest that 6–
55% of patients with NAFLD have NASH, depending on the patient inclusion criteria and the 
definition of NASH.17–19 Nonetheless, patients undergoing liver biopsy are highly selected and are not 
representative for a community. In a study of 328 unselected patients attending an out-patient clinic 
in the Southwest of the US, 46% had NAFLD based on patient history and ultrasonography findings.12 
Of those with NAFLD, 134 (of 156 in total) underwent liver biopsy, of whom 40 were found to have 
NASH, suggesting an NASH prevalence of 12% in the general population. Furthermore, using a score 
validated against liver histology, a Finnish group estimated the population prevalence of NASH to be 
around 5%.20  
 
With ongoing necroinflammation and liver injury, patients with NASH will develop progressive liver 
fibrosis and, finally, cirrhosis. Advanced fibrosis or cirrhosis due to NASH has a similar mortality than 
when these features are caused by chronic hepatitis C virus infection and advanced liver disease. The 
annual incidence of HCC in patients with NASH-related cirrhosis is 1–2%21. In the United States, 
NASH has already become the second-leading aetiology of liver disease requiring liver 
transplantation in adults.22 Importantly, the number of patients with NASH on the transplantation 
waiting list increased by 170% from 2004 to 2013, the largest absolute and relative increase 
compared with other aetiologies. Hepatic complications represent the third most common cause of 
death in patients with NAFLD or NASH, after cardiovascular events and malignancies.4  
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[H3] Asia, Africa and Pacific Islands. The epidemiology of NAFLD in Asia-Pacific and African countries 
is shaped by significant differences in lifestyle and economic growth among countries and between 
urban and rural areas within the same country. For example, in China the prevalence of NAFLD is 
higher in coastal and urban areas (up to 30%) than in inland and rural areas (around 1%).23 In urban 
areas, the prevalence of NAFLD is around 15–30% in Asia-Pacific countries and 10–20% in Africa.  
 
Compared with Western countries, the increase in NAFLD prevalence over time is more marked in 
Asia and the Pacific areas, probably reflecting rapid lifestyle changes. Studies from Japan and China 
recorded a twofold increase in the prevalence of NAFLD over a decade.23,24 In contrast, the reported 
prevalence of NAFLD in the United States was already around 30-40% in 2004 and has not increased 
substantially thereafter14. The incidence of NAFLD is difficult to study because ultrasonography 
cannot reliably quantify liver fat. Nevertheless, according to a recent study from Hong Kong using 
paired 1H-MRS, 13.5% of community subjects developed NAFLD in 3–5 years.25 Asians and Pacific 
Islanders develop obesity-related complications at a lower body mass index (BMI) than Europeans 
and Americans because of the tendency to have central fat accumulation. As a result, around 15–
20% of Asian patients with NAFLD do not have obesity according to Western definitions.  
 
Data on the prevalence of advanced disease in the general Asia-Pacific and African populations are 
scarce. One population study in Hong Kong using transient elastography and serum markers of 
fibrosis suggests that around 4% of the patients with NAFLD in the community have advanced 
fibrosis or cirrhosis.26 In high risk groups, such as patients with type 2 diabetes, advanced fibrosis 
and cirrhosis can be found in 10–20% of patients.  
 
 
[H2] Children and Adolescents 
[H3] The United States and Europe. NAFLD is the most common liver disease in children and 
adolescents (Table 2). Similarly to adult patients, NAFLD is associated with obesity and metabolic 
syndrome27 and probably with elevated alanine aminotransferase (ALT) levels in blood and PNPLA3 
polymorphisms 28 ( Figure 1)29. A recent analysis of the National Health and Examination Survey, 
including data from >12,000 12–19 year-old Americans, showed that NAFLD prevalence (with NAFLD 
defined as BMI > 85th percentile and elevated ALT levels of >22.1 U/L for girls and >25.8 U/L for boys) 
more than doubled over the past two decades27. The associated risk factors identified in this study 
confirm previously identified factors such as age, increased BMI, male gender and Mexican-
American race30. Modifiable factors were increased consumption of sugar-sweetened beverages and 
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other lifestyle factors (such as a sedentary behaviour) 27. Paediatric NAFLD prevalence has been 
predicted to increase even further31.  
Ethnicity has a role is NAFLD risk in children as well. Given similar BMI and metabolic syndrome 
features, black and non-Hispanic children have a lower risk of developing liver disease than Hispanic 
children (reviewed in29). Hereditability, particularly in first-degree relatives, is documented. Indeed, 
59% of siblings and 78% of parents of children with fatty liver will develop NAFLD as well32. Age is 
another striking factor; one post-mortem study in California showed that 17% of teenagers had 
NAFLD compared to 0.7% of 2–4 year olds, owing both to a longer period to accumulate steatosis as 
well as an increased incidence in adolescents 30. [Au: OK? Ok now]  
[H3] Asia, Africa and Pacific Islands. Given that obesity and overweight are important risk factors for 
NAFLD, the prevalence of NAFLD in Korea is greater in patients admitted to obesity clinics (71.9% 
based on ultrasonography measures and 61.8% based on serum ALT levels) than in general health 
clinics (8.7% based on ultrasonography measures and 5.9% based on serum ALT levels)33. In most of 
Asia, a significant difference is reported between urban and rural populations with a prevalence of 
16–32% in urban areas versus 9% in rural populations34. Obesity-related NAFLD was reported in 64 
of 84 Chinese children (77%) in one study35. In Australia, the prevalence of NAFLD in the paediatric 
population was estimated to be approximately 10% in the total population and 27.6% among 
overweight and obese children36.  
 
[H1] Mechanisms/pathophysiology 
[H2] Pathophysiology of NAFLD  
 
Fatty liver disease is characterized by hepatic steatosis; there may also be varying degrees of liver 
cell injury, inflammation and in some cases, fibrosis (Figure 2).  
 
[H3] The evolution of hepatic steatosis in obesity. Several factors contribute to hepatic lipid 
accumulation in the setting of obesity. First, weight gain is associated with marked expansion of 
adipose tissue, which leads to dysfunction and eventual death of adipocytes. Adipose tissue 
dysfunction results in local inflammation and up-regulation of cytokines that promote insulin 
resistance. Insulin-resistance, in turn, compromises the ability of adipocytes to store fat, resulting in 
release of free fatty acids into the circulation, which then become available for uptake by ectopic 
organs such as the liver.37 As a consequence of obesity-related adipose tissue dysfunction, the liver is 
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exposed to high levels of circulating free fatty acids as well as high levels of insulin produced to 
compensate for adipocyte insulin resistance. Hepatocytes take up these fatty acids via transporters 
FATP5 and CD36, which are also up-regulated in obesity.38,39 Fatty acid accumulation in hepatocytes 
prompts the synthesis of triglyceride; during this process, diacylglycerol intermediates accumulate, 
which impair hepatic insulin signalling by activating protein kinase C epsilon (PKC ).40 Hepatocyte 
insulin resistance fuels gluconeogenesis, promoting hyperglycaemia and prompting even more 
compensatory insulin production.  
 
The liver itself can contribute to steatosis by producing lipid from carbohydrate in a process called de 
novo lipogenesis (DNL). The enzymes responsible for DNL are up-regulated by insulin and glucose 
through the action of two transcription factors, sterol regulatory element binding protein-1 (SREBP1) 
and carbohydrate response element binding protein (ChREBP).41 In the normal liver, DNL is not a 
major source of hepatic lipid, but in the setting of obesity and hyperinsulinaemia, it can contribute 
as much as 25% of total hepatic lipid stores, and is considered an important factor in the 
development of NAFLD.42,43 Why an insulin-dependent process such as DNL would be up-regulated in 
hepatocytes if uptake of excess circulating fatty acids has rendered them insulin-resistant seems 
paradoxical. One explanation is that hepatocyte insulin resistance manifests downstream from the 
insulin receptor per se;44 another is that DNL can also be induced by insulin-independent pathways 
such as endoplasmic reticulum stress-mediated activation of SREBP145.  
 
Nutrients from the diet also serve as substrates for hepatic triglyceride synthesis and thus 
participate in the development of hepatic steatosis. Dietary sugars are converted to fatty acids via 
DNL and dietary fats are taken up by the liver in parallel with adipose tissue-derived fatty acids. 
Roughly 40% of the lipid that accumulates in a fatty liver derives from dietary sugars and fats. 
Lipolysis of dysfunctional adipose tissue contributes the remaining 60%.46  
 
[H3] The gut–liver axis in NAFLD. Interactions between the intestine and the liver are emerging as 
important determinants of NAFLD. Obesity, which represents the background for NAFLD, is 
associated with alterations in the intestinal microbiome that enhance nutrient extraction from the 
diet47. To date, NAFLD has not yet been linked to any specific microbiotic signature, but people with 
NAFLD have an intestinal microbiome that is clearly different from that of healthy individuals48. 
Intestinal dysbiosis can contribute to liver disease by weakening the intestinal barrier and enabling 
the translocation of bacteria or bacterial products such as endotoxin or ethanol into the portal 
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circulation. Dysbiosis can also lead to the luminal degradation of beneficial nutrients such as choline, 
which are important for maintenance of hepatic lipid homeostasis11.  
 
[H3] Mechanisms of cell death in a fatty liver. One of the hallmarks that differentiates NASH from 
NAFLD is the presence of hepatocellular injury. Hepatocytes can be damaged by several mechanisms 
in the setting of NAFLD. First, the demand for metabolism of excess fatty acids places strain on 
hepatocyte mitochondria; over time this leads to mitochondrial uncoupling, production of reactive 
oxygen species (ROS) and activation of Jun N-terminal kinase (JNK)49. Once initiated, ROS production 
and JNK activation continue in a feed-forward loop, which results in mitochondrial damage, impaired 
ATP production and cell death50,51. Excess fatty acids can also injure hepatocytes by inducing 
endoplasmic reticulum stress, which this leads to mitochondrial dysfunction and cell death via 
caspase-2-mediated cleavage of the BH3-only protein BID52–54. Yet another pathway via which fatty 
acids can kill hepatocytes is through activation of death receptors. Several death receptors (FAS, DR5 
(also known as TRAIL-R2), TNFR1) are up-regulated on hepatocytes in the setting of steatosis; death 
receptor activation has been implicated as an important stimulus to hepatocyte apoptosis and 
necroptosis in NASH55–58.  
 
[H3] Inflammation and fibrosis in fatty livers. Activation of the immune system is a key feature of 
NASH. The classic effectors of hepatic inflammation in NASH are Kupffer cells and recruited 
macrophages, but natural killer T cells play an important part in macrophage recruitment59 and both 
natural killer T and T cells are emerging as contributors to progressive liver disease60–64. Several 
compounds can trigger inflammation in fatty livers — including fatty acids, bacterial endotoxin 
reaching the liver from the intestine, and damage-associated molecular patterns (DAMPs) released 
from dying hepatocytes — and induce inflammation by activating Toll-like receptors (TLRs) and 
inflammasomes in target immune cells65,66, stimulating the production of an array of cytokines and 
chemokines59,67,68.  
 
The development of hepatic fibrosis portends a poor outcome in NASH.7 The central event in hepatic 
fibrogenesis is activation of hepatic stellate cells69; these cells are susceptible to stimulation by a 
variety of compounds present in a diseased fatty liver. Like inflammatory cells, stellate cells can be 
activated by DAMPs from dying hepatocytes or other sources that engage TLRs on the cell surface70. 
Other compounds such as free cholesterol can amplify hepatic fibrosis by up-regulating TLR 
expression on stellate cells71. Oxidant stress can also activate stellate cells; advanced glycation end 
products, which are abundant in diabetics, induce ROS production by stellate cells by inducing the 
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enzyme NOX272. One unique consideration in NASH is the role of ballooned hepatocytes in hepatic 
fibrosis. Ballooned cells produce sonic hedgehog73, a protein that promotes tissue fibrosis74. 
Whether hedgehog stimulates fibrosis through direct effects on stellate cells or indirect effects on 
fatty liver injury is currently under study75.  
 
[H2] Genetics  
A substantial proportion of the population are at risk of progressive NAFLD (that is, progression to 
NASH with advanced fibrosis/cirrhosis) owing to obesity and insulin resistance. However, only a 
minority of people with NAFLD progress to more advanced disease including hepatocellular 
carcinoma76. The reasons for this remain incompletely understood, but NAFLD is best considered a 
complex disease trait, the development and progression of which are attributed to subtle inter-
patient variations including host genetic factors and environment interact to produce disease 
phenotype and determine disease progression.. Although the presence of NAFLD is principally 
determined by environmental factors, genetic factors contribute and, crucially, determine how 
individuals respond to the challenge of caloric excess and consequent metabolic stressors.  
Until 2008 , studies looking for genetic variants involved in susceptibility to NAFLD have been 
restricted to case–control allelic association studies limited by the fact that they are reliant on a 
priori hypotheses for gene selection. Candidate genes are drawn from the limited pool of genes of 
which biological function is understood and considered relevant to the disease. Only a minority of 
genes associated with NAFLD through candidate-gene analysis have been independently validated in 
large independent studies or through the use of transmission disequilibrium testing. This short list 
includes mitochondrial superoxide dismutase 2 (SOD2)77, phosphatidylethanolamine N-
methyltransferase (PEMT)78, fatty acid desaturase 179 and kruppel-like factor-6 (KLF6)80. All of these 
genes were associated with progressive NAFLD rather than NAFLD per se. More recently, a number 
of novel genetic associations with NAFLD have been identified through genome-wide association 
studies (GWAS)81–88. Two of these associations are worthy of particular attention due to their 
reproducibility in several GWASs, their association with histologically advanced disease in 
subsequent association studies and their biological plausibility — at least as genes clearly involved 
hepatic lipid metabolism. 
 
The first of these genes encodes PNPLA381. The index single nucleotide polymorphism (SNP) in 
PNPLA3 (rs738409 c.444 C>G, p.I148M) is a non-synonymous cytosine to guanine nucleotide 
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transversion mutation that results in an isoleucine to methionine amino acid change at codon 148. A 
gene dosage effect for PNPLA3I148M carriage is observed with a stepwise increase in 1H-MRS 
determined hepatic triglyceride content (HTGC) with increasing carriage of the minor allele81. The 
minor-allele frequency also correlates with ethnic differences in susceptibility to NAFLD. Multiple 
histologically based studies have clearly demonstrated that the PNPLA3I148M variant is associated 
with the severity of steatohepatitis and fibrosis89 and more recently with the presence of HCC90. 
PNPLA3 might, therefore, be used as part of an HCC surveillance strategy. The PNPLA3I148M SNP has 
also been associated with a greater response to dietary or lifestyle modification and may therefore 
be a biomarker for both greater risk of progressive disease and also greater benefit from 
intervention. The precise mechanism by which the PNPLA3I148M SNP contributes to disease remains 
controversial despite intensive study, although alterations in lipid droplet architecture and in retinol 
metabolism of the hepatic stellate cell have been associated with the PNPLA3I148M variant91,92. 
The second of these genes encodes a transmembrane superfamily member TM6SF2 on chromosome 
19, with a non-synonymous SNP (rs58542926 c.449 C>T, p.E167K) associated with 1H-MRS-quantified 
HTGC87. As with PNPLA3, candidate gene studies have shown that the TM6SF2E167K variant is also 
associated with progressive NAFLD93. Interestingly, evidence has been provided that carriage of the 
more common TM6SF2E167K major allele is associated with dyslipidaemia (raised serum LDL 
cholesterol and triglyceride), increased myocardial infarction and cardiovascular disease risk 
whereas minor allele carriage is protective94. Functional studies suggest that TM6SF2 regulates 
hepatic lipid efflux, with its deletion or mutation resulting in a reduction in lipoprotein secretion 
(very low density lipoprotein (VLDL), triglycerides and APOB) leading to increased hepatocellular lipid 
droplet size and triglyceride accumulation. The TM6SF2E167K results in lower total cholesterol in 
humans and expression levels of the variant are lower than the wild-type form. These data indicate 
that the TM6SF2E167K variant confers a ‘loss-of-function’ to the protein that may be both qualitative 
and quantitative94.  
Although these studies fail to provide any explanation for the association between the TM6SF2 
variant and progressive NAFLD they do suggest an interesting paradox – the ‘TM6SF2 Catch-22‘ 
paradigm95. Here, on a background of insulin resistance and metabolic stress, TM6SF2 genotype acts 
as a determinant of metabolic syndrome-related end-organ damage and clinical outcome: protecting 
the liver at the expense of increased risk of atherosclerosis and cardiovascular disease or vice versa. 
The best evidence in support of this paradigm has recently been provided by a study in patients with 
NAFLD demonstrating that although the minor threonine SNP (TM6SF2E167K) is associated with 
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advanced disease, carriage of the major cysteine allele (TM6SF2167E) is associated with dyslipidaemia 
and cardiovascular disease96. 
 [H2] Epigenetics  
The role of epigenetic factors in the biology of NAFLD is starting to emerge and has enabled 
integrating the information on gene expression with the external and internal metabolic information 
(Figure 3). Epigenetic alterations orchestrate the reprogramming of transcriptional machinery of 
hepatocytes, which occurs during their adaptation to a lipotoxic environment, inflammation and 
oxidative stress. These epigenetic changes could at least partially explain why the degree of 
histological damage and/or recovery differs among individuals with an identical genetic background 
(for example presence of PNPLA3I148M risk allele97) and in response to similar injury (that is, fat 
overload) .  
 
[H3] DNA methylation. DNA methylation in particular is suggested to be involved in the progression 
of NAFLD towards advanced (fibrotic) clinical stages. Joined global expression and methylation 
analysis of human liver specimens demonstrated that advanced disease is associated with global 
deregulation (mostly hypomethylation) of methylation in multiple CpG sites98. Hypomethylation and 
increased expression of genes involved in tissue repair, regeneration and tumorigenesis were found, 
as were hypermethylated transcriptionally repressed genes that are involved in basic metabolic 
functions (such as lipid, urea and amino acid metabolism) or belonged to the cytochrome P450 
family98. In addition, DNA hypomethylation was associated with transdifferentiation of stellate cells 
into myofibroblasts in cell models, a phenomenon commonly associated with fibrosis99. Abnormal 
methylation of the PNPLA3 promoter was associated with fibrosis severity in a large number of 
Japanese people100. Differences in the methylation status at specific CpG islands within the promoter 
of anti-fibrogenic (PPARA and PPARD) and pro-fibrogenic (TGFB1, COL1A1 and PDGFA) genes might 
have a prognostic value in differentiating patients with mild fibrosis from those with advanced 
fibrosis101. 
 
Liver-specific epigenetic changes that affect physiological processes and lead to perturbations of 
normal hepatocyte and mitochondrial function not only affect the progression of NAFLD but also 
NAFLD-related metabolic phenotypes, such as insulin resistance. Targeted analysis of the 
methylation status of the peroxisome proliferator-activated receptor gamma coactivator 1  
(PPARGC1A) — a master transcriptional regulator of glucose and lipid metabolism and mitochondrial 
biogenesis — showed that methylation levels significantly correlated with plasma insulin levels, β-
cell function and the HOMA-IR marker for insulin resistance (calculated as (glucose mmol/L × insulin 
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mU/ml)/22.5) in humans102. A complex interaction between PPARGC1A mRNA levels and liver 
mitochondrial DNA (mtDNA) copy number was also reported. Interestingly, low mtDNA copy number 
was also directly associated with insulin resistance and NAFLD102. metylation of mtDNA might have a 
role in modulating the liver phenotype beyond genomic DNA103. Specifically, methylation and 
transcriptional activation of the mitochondrial-encoded NADH dehydrogenase 6 (MT-ND6), which is 
involved in oxidative phosphorylation, in the liver was associated with more advanced liver 
pathology in humans103.  
 
A possible explanation for the changes in DNA methylation in NAFLD is its association with obesity, 
which has been suggested to be associated with reduced DNA demethylation104. Furthermore, 
evidence suggests that the activity of 5-hydroxymethylcytosine (5hmc) might be an additional 
mechanism that explains liver DNA-demethylation pathways in patients with NAFLD105.  
 
Epigenetic changes can be potentially inherited from one generation to the next. For instance, an 
experimental study in rodents showed that liver injury induced by the hepatotoxin carbon 
tetrachloride (CCl4) led to hypomethylation in the PPARG gene promoter and associated chromatin 
modifications in sperm, in stem cells and/or mature sperm106. Although this experimental study 
suggests that the hepatic wound healing response might be heritable, it remains unknown whether 
the same is true in patients with NAFLD. In addition, epigenetic alterations acquired during 
development may contribute to foetal metabolic programming107. Maternal protein restriction in 
rodents led not only to fatty liver in the offspring but reduced life span; further in vitro analysis 
showed that these changes were associated with changes in DNA methylation108. Likewise, in utero 
overnutrition affects a sirtuin-mediated histone acetylase/deacetylase pathway that impacts on the 
hepatic histone code of the progeny, as shown in a nonhuman primate experimental model of high 
fat diet-induced NAFLD109. 
 
[H3] Non-coding RNAs. A large part (~ 60%) of the cellular gene-expression machinery is regulated 
by non-coding RNAs (ncRNA) — RNA transcripts that do not encode proteins (Figure 3). MicroRNAs 
(miRNAs) have been studied extensively in liver disease research, and evidence for their role in 
NAFLD is consistent. A number of miRNAs have been implicated in NAFLD severity, liver injury and 
lipid metabolism, including miR-122, miR-192, mir-375 and miR-34a110–112.  
 
Of particular importance in the pathophysiology of NAFLD is miR-122, expression of which is highly 
enriched in healthy liver. Its network of regulated-genes are involved in cholesterol metabolism113, 
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modulation of liver inflammation and progression of hepatocarcinogenesis114. An in vitro study 
showed that miR-122 regulates collagen production in hepatic stellate cells suggesting a pivotal role 
in liver fibrogenesis115. Notably, expression levels of miR-122 are decreased in the liver of patients 
with NAFLD whereas levels are increased in the circulating (extracellular) compartment 112; rodent 
models of diet-induced steatohepatitis confirmed these findings116. This marked down-regulation of 
liver miR-122 observed in NAFLD seems to be of particular relevance in the pathogenesis of the 
disease. In fact, silencing of miR-122 is an early event during hepatocarcinogenesis as a consequence 
of NASH in humans117. Whether the down-regulation of miR-122 in the liver is the cause or the 
consequence of the progression of NAFLD remains to be investigated, because of the cross-sectional 
nature of the above-mentioned studies.  
 
Several studies have explored the role of circulating (extracellular) miR-122 levels as biomarker of 
NASH — or disease progression — in humans, because miR-122 levels significantly correlate with 
histological damage (including hepatocellular ballooning, degeneration and fibrosis) and elevated 
liver enzymes (a marker for liver inflammation or injury) 112. A two-stage study, exploring a large 
panel of circulating miRNAs at different stages of NAFLD, showed that circulating levels of miR-122 
were increased 7.2-fold in patients with NASH versus healthy controls, and 3.1-fold in NASH versus 
simple steatosis112. Although the performance of circulating miR-122 suggests that it could be a 
reliable biomarker of liver injury in NAFLD, the overall predictive value for liver fibrosis is very similar 
to currently available non-invasive measurements, including serum cytokeratin-18 levels112. 
Nevertheless, the research agenda is still open; for instance, preliminary data from a rat model of 
Roux-en-Y gastric bypass showed that circulating miR-122 levels decrease after surgery, suggesting a 
putative role as biomarker of response to therapeutic interventions118. Clinical evidence has 
suggested that bariatric surgery was able to partially reverse epigenetic alterations in the liver 
associated with NAFLD. Notably, reversing differentially methylated sites in NAFLD correlates with 
improvement in liver histology119. 
 
Furthermore, miR-122 released from the liver circulate in the bloodstream — such as an hormone — 
capable of integrating global metabolic signalling 112. A functional polymorphism in the 3′ UTR 
region of a validated miR-122 target gene (that is, rs41318021 of SLC7A1), was significantly 
associated with arterial hypertension, suggesting that miR-122 might potentially modulate the 
susceptibility to elevated blood pressure in people who carry the risk allele of this variant 112. 
Moreover, the expression levels of liver miR-122 significantly and negatively correlated with systolic 
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arterial blood pressure 112. Together, the reduction of miR-122 levels in NAFLD might explain in part 
the connection between NAFLD and cardiovascular risk.  
 
Finally, although the role of long non-coding RNAs (lncRNAs) in the pathophysiology of NAFLD 
remains largely unknown, that they are implicated in lipid homeostasis. For instance, a liver-enriched 
lncRNA in mouse regulates lipoprotein lipase activation through an FXR-mediated pathway120.  
 
 
 
-
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[H3] Ultrasound-based techniques. The leading quantitative ultrasound biomarker for hepatic 
steatosis is the controlled attenuation parameter (CAP)136 determined, which is a quantitative 
measure of the attenuation (energy loss) of the ultrasound beam as it traverses the hepatic 
parenchyma. The rationale is that ultrasound energy is attenuated more by fat than by non-fatty 
tissue; hence, greater attenuation implies greater fat content. The parameter is measured with the 
same device used in vibration-controlled transient elastography (VCTE, see below) and reported in 
units of dB/m137. An anatomic image is not acquired, therefore, the location where the 
measurements were made is not recorded. Numerous single-centre studies suggest that CAP can 
accurately identify patients with hepatic steatosis138–140. However, due to overlap in CAP values 
across steatosis grades, CAP has limited accuracy for steatosis grading138,139. Also, the reproducibility 
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of CAP values in patients with NAFLD has not been studied extensively. Although CAP shows 
promise, more data is needed before CAP can be considered a valid biomarker of hepatic steatosis.  
 
[H3] MRI. The leading quantitative magnetic resonance imaging (MRI) biomarker for hepatic 
steatosis is proton density fat fraction (PDFF)141. This biomarker measures the relative proportion of 
mobile protons attributable to fat and correlates closely with biochemically determined hepatic 
triglyceride concentration141. [Au: Some information moved to the figure legend.] In numerous 
single-centre and multi-centre studies, PDFF has shown high accuracy for diagnosing, grading, and 
longitudinally monitoring steatosis in adults and children, including morbidly obese individuals142–147. 
Historically, measurement of PDFF required MRS, which usually is available only in academic centres 
and generally assesses only portions of the liver. In recent years, advanced MRI techniques have 
been developed that measure PDFF throughout the entire liver in a single breathhold, thereby 
eliminating sampling variability. These techniques are becoming commercially available on the latest 
generation of MR scanners made by the leading manufacturers. Importantly, PDFF measurements 
made on scanners of different field strength and manufacturer agree closely146–148. With appropriate 
quality control, these advanced PDFF-estimation techniques can be used in clinical trials (Figure 5A).  
 
 
-
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 [H3] Biomarkers and scores.
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[H3] Ultrasonography. Conventional ultrasonography, in which standard B-mode (grey scale) 
ultrasonographic images are acquired and interpreted qualitatively, is frequently used to screen for 
hepatic steatosis, but conventional ultrasonography is insensitive to mild steatosis, especially in 
obese individuals, and is limited by reader variability 155,156.  
 
[H3] Elastography. Imaging techniques collectively known as elastography have been developed to 
indirectly measure tissue stiffness non-invasively. The measurement involves the assessment of the 
propagation of shear waves within the liver, from which the hepatic stiffness is inferred. Depending 
on the device, results can be reported as shear wave speed in m/s or as one of several elastic moduli 
(e.g., Young modulus, complex shear modulus) in kPa157. These various elastography-derived 
parameters have emerged as the leading imaging biomarkers of hepatic ‘fibrosis’. 
[H3] Ultrasound-based elastography. The first ultrasound-based method to measure liver stiffness 
was VCTE158. This technology uses a non-imaging device to track shear waves transmitted transiently 
into the liver by an external vibration source; an anatomical image is not acquired and the location 
from which the measurements are made is not recorded.  
More recently, elastography capabilities have been added to clinical ultrasound scanners157. 
Elastography-enabled scanners use ultrasound to track shear waves generated transiently in situ 
within the liver by an ultrasound push pulse (also known as an acoustic radiation force impulse); 
measurement locations are recorded on an anatomical image157,159,160 (Figure 5b). Because each 
manufacturer uses proprietary hardware and software, measurements made with different devices 
and even with different transducers (probes) on the same device do not agree160,161. Thus, any given 
patient should be monitored with a single device and using the same probe. VCTE and elastography-
enabled scanners have been shown to provide high accuracy for the diagnosis of advanced fibrosis in 
patients with viral hepatitis162,163. Single-centre studies suggest these devices accurately diagnose 
advanced fibrosis in NAFLD as well163, although multi-centre validation studies have not yet been 
performed. None of these devices can diagnose early fibrosis accurately. The technical success rate, 
reliability, robustness and precision of these devices for measuring stiffness parameters in NAFLD 
has not been extensively studied160. Until such data becomes available, caution is advised for use of 
these devices in NAFLD clinical trials.  
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[H3] MR based elastography. Magnetic resonance (MR) elastography uses a specialized MRI 
sequence to visualize shear waves delivered continuously into the liver by an external acoustic 
source164. The wave images are processed by a so-called inversion algorithm to generate 
‘elastograms’165 (Figure 5c). These computer-generated images depict the spatial distribution of a 
stiffness parameter known as the magnitude of the complex shear modulus (usually referred to as 
‘shear stiffness’ in the medical literature). The hepatic stiffness is recorded from representative 
portions of the liver. MR elastography now is commercially available on commercial MRI scanners, 
with the same hardware to generate the shear waves and the same inversion algorithm to process 
the wave images. Small single-centre studies in healthy volunteers suggest that measurements made 
with different scanners agree166. Large studies in patients with NAFLD are needed to confirm cross-
platform reproducibility.  
In single-centre studies, MR elastography has been shown to diagnose advanced fibrosis in adult 
NAFLD with high accuracy167–169. Accuracy of MR elastography probably is higher than that of 
ultrasound-based elastography170. As with ultrasound-based techniques, accuracy for detection of 
early fibrosis is modest. The precision of MR elastography in the NAFLD population has not been 
studied extensively. Multi-centre validation studies are needed before MR elastography can replace 
biopsy in NAFLD clinical trials.  
 
-  
-
 –
–
-
-
- - -  
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[H1] Management  
[H2] Current management of NAFLD 
[Au: Are treatments (incl. lifestyle changes) only encouraged when NASH has developed (and not 
in the earlier stages – fatty liver, steatosis)? Please add a short sentence to specify this.]The first 
step in the management of NASH in most patients is implementation lifestyle modifications that 
focus on healthy eating habits and regular exercise171. Without biopsy confirmation of the presence 
of NASH, lifestyle modification is still appropriate to reduce cardiovascular risks in patients with 
NAFLD and also to treat NASH if it is present. Weight loss for overweight and obese patients is 
recommended based on the collective observations from multiple studies showing that histological 
improvement can occur when patients lose 5–10% of body weight172,173. Unfortunately, meaningful 
lifestyle modification is difficult to achieve and difficult to sustain for most people174,175 and, 
therefore, alternatives are needed to treat NASH and prevent the associated complications of the 
metabolic syndrome. At this time, no pharmaceutical treatments are approved for NASH, although 
many agents are in various stages of evaluation in clinical trials. Bariatric surgery is a good option for 
select obese patients with NASH as it typically leads to improvement in NASH176,177. 
 
[H2] Pathogenesis-based targets of therapy 
One perspective on the pathogenesis of NASH is that lipotoxic lipid species, which are derived from 
an excess supply of fatty acids in hepatocytes, mediate the cellular injury and resulting inflammatory 
and fibrotic response that results in the histological phenotype of NASH178–180. This paradigm enables 
us to predict therapeutic interventions that might prevent or treat NASH by targeting the oversupply 
of fatty acids to the liver, the generation of lipotoxic intermediates and the resulting dysfunctional 
cellular responses (Figure 7). Given that the best treatments of disease are those that target 
underlying causes at a fundamental level, an ideal approach would be to pharmacologically 
manipulate the pathways of energy metabolism responsible for the heterogeneity in human energy 
efficiency.  
 
If the genomic or epigenetic changes responsible for these differences can be identified and 
exploited, then treatments could be effective for NASH as well as the underlying insulin resistance, 
hypertension, hyperlipidaemia and other manifestations of the metabolic syndrome that lead to 
disability and early death181. Animal studies have provided some insights into these differences but 
how these will be translated into treatment of human disease is yet to be shown. Examples include 
the divergence of rat strains into those having high and low exercise tolerance with features of the 
metabolic syndrome developing in the latter182, the role -adrenergic stimulation of highly metabolic 
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brown adipose tissue183, the role of serotonin in modulating metabolism184, and the role of 
peripheral cannabinoid signalling in modulating energy efficiency185. At this time, insights into the 
regulation of energy metabolism are mostly at early preclinical stages and clinical trials have 
generally focused on manipulating more downstream processes such as lipogenesis, lipolysis, 
inflammation, oxidant stress and fibrogenesis.  
 
[H2] Preventing an oversupply of fatty acids in the liver 
[H3] Inhibition of de novo lipogenesis. One approach to reducing lipotoxic liver injury is to reduce 
the endogenous production of fatty acids in the liver by inhibiting DNL. The transcription factor 
SREBP1C is a major regulator of DNL; thus, treatments that decrease SREBP1C may be beneficial. 
This is one potential mechanism by which the bile acid derivative obeticholic acid may work. As an 
activating ligand for the nuclear receptor FXR, obeticholic acid increases the expression of SHP1 
which decreases the expression of SREBP1C186. A Phase II clinical trial of obeticholic acid has 
demonstrated histological improvement in NASH after 72 weeks (45% versus 21% in placebo-treated 
patients, P=0.0002)187. However, treatment was associated with significant pruritus in 23% in the 
treatment group compared with 6% in the placebo group and with a rise in total and LDL cholesterol 
and a decrease in HDL cholesterol in treated patients, the importance of which will be further 
assessed in another clinical trial.  
 
Another approach to inhibiting DNL includes using inhibitors of key enzymes in the pathway of fatty 
acid synthesis such as acetyl-CoA carboxylase (ACC) and such agents are being evaluated in clinical 
trials. Augmenting the incretin axis with GLP-1 analogues such as exenatide or impairing the 
breakdown of endogenous GLP-1 with the DPP-4 inhibitors (gliptins) may also decrease hepatic 
lipogenesis by decreasing substrate availability and this approach is also being examined in clinical 
trials.  
 
[H3] Reducing the burden of fatty acids delivered to the liver. Lipolysis of stored triglyceride in 
adipose tissue is the major source of fatty acids delivered via the circulation to the liver. Adipose 
tissue lipolysis is normally suppressed by insulin, but when adipose tissue is insulin resistant it 
continues to release fatty acids into the blood at inappropriate times contributing to the 
development of NASH188. The PPARγ ligand thiazolidinediones (TZDs or ‘glitazones’) have been 
shown to improve adipocyte insulin responsiveness and thus decrease inappropriate lipolysis. One 
TZD, pioglitazone, has been shown to improve adipose insulin sensitivity and improve NASH189,190. 
Unfortunately, this benefit comes at the expense of increased body weight in some patients because 
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of adipocyte triglyceride retention. This and possibly other adverse effects such as osteoporosis and 
bladder cancer have dampened the enthusiasm for using pioglitazone for NASH and it has not gained 
widespread use.  
 
Metformin is another insulin sensitizing agent but its effect is primarily in the liver. There is little 
evidence that hepatic insulin resistance plays a role in causing NASH. A large randomized clinical trial 
(RCT) of metformin in children did not show any benefit on ALT levels or histology but fortunately 
neither did it show worsening191. Nonetheless, metformin may play an adjunctive role in the 
treatment of NASH because it is often associated with weight loss and recent data indicates that it is 
associated with a reduced risk of a number of malignancies192.  
 
Fatty acids and the carbohydrates used to make fatty acids can also be diverted to oxidative 
pathways and this may explain the benefit of regular exercise in improving the metabolic syndrome. 
Oxidative pathways can be stimulated pharmacologically as well. The PPARA/PPARD ligand GFT505 
was recently evaluated in a clinical trial because it improves insulin sensitivity, which may be 
explained by the effect of PPARA on promoting oxidative metabolism in the liver and PPARD in 
promoting oxidative metabolism in muscle193. 
 
[H2] Reducing injury  
The mechanisms of lipotoxic injury remain uncertain but oxidant stress has been proposed to have a 
role194. Oxidant stress with associated lipid peroxidation clearly occurs in NASH195, but whether it is 
causative or an epiphenomenon remains unknown. Two large RCTs of natural vitamin E (d-  
tocopherol) at a dose of 800 IU daily have been conducted, one in adults (PIVENS) and one in 
children (TONIC). The PIVENS trial demonstrated improvement in liver histology in 43% compared to 
a placebo response of 19% (P=0.001)190 and similarly the TONIC trial showed resolution of NASH in 
58% compared to 28% in placebo (P=0.006)191. For neither trial has there been evidence that indices 
of oxidant stress improved, so it remains somewhat unclear how vitamin E improves NASH. Both the 
PIVENS and TONIC trials were conducted in patients without diabetes or cirrhosis so the benefits of 
vitamin E in patients with these commonly associated conditions remain unknown. Concern has 
been raised about the cardiovascular safety of high dose vitamin E and, consequently, patients and 
doses should be carefully selected. The ideal patient may be someone with aggressive NASH and no 
diabetes or major risks for cardiovascular disease, but such patients comprise a relative minority. It 
should be noted that weight loss has an additive benefit in patients treated with vitamin E, so the 
use of vitamin E should be an adjunct to weight loss and not an alternative196. Fish oil (poly n-3 fatty 
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acids) may also exert beneficial effects on lipid peroxidation but a large trial of ethyl-eicosapentanoic 
acid in NASH patients did not show any benefit197. 
 
Endoplasmic reticulum stress is another process known to occur in NASH that may be central to the 
pathogenesis of lipotoxic hepatocellular injury. Studies of agents that diminish the endoplasmic 
reticulum stress response have provided provocative data in animals but these have yet to be 
introduced into RCTs198. 
 
The contribution of hypercholesterolaemia to the development of steatohepatitis and liver fibrosis 
has not been fully established but a number of studies suggest that it may have a role in some 
patients. A morphometric study of liver biopsies demonstrated cholesterol crystals in lipid droplets 
in patients with steatohepatitis but not steatosis199. Statin use is safe in patients with liver disease200 
and a Cochrane review concluded that statins can improve steatosis and reduce aminotransferase 
levels but treatment trials with histological endpoints are lacking201. More recently, in a large 
European observational cohort with NAFLD, statin use was associated with less steatosis, NASH and 
fibrosis in a dose-dependent manner; interestingly the presence of the PNPLA3I148M polymorphism 
prevented the protective effect of statins202. In another recent study, statin use in NAFLD patients 
was associated with a reduction in liver related deaths, liver transplants or other liver outcomes7.  
 
[H2] Inhibition of inflammation  
The role of inflammation in contributing to hepatocellular injury versus a consequence of injury is 
unknown but should be clarified by the results of clinical trials examining various anti-inflammatory 
approaches. One clinical trial of an anti-inflammatory phosphodiesterase-4 (PDE4) inhibitor was 
negative despite the demonstration of reduced circulating TNFα levels in patients given the active 
agent203. However, like all contributors to the pathogenesis of NASH, inflammation may play an 
important role in only a subgroup of patients. Post-hoc analysis of RCT results to identify and then 
predict responders to a specific therapy will be essential for all agents. 
 
[H2] Inhibition of apoptosis  
Caspase inhibitors have been developed and are in RCTs for a number of diseases including NASH 
based on the recognized role of hepatocellular apoptosis in the pathogenesis of NASH204. Although 
this might be a rational approach in acute processes, theoretical concerns about the safety of long 
term inhibition of apoptosis persist with this treatment approach in NASH.  
 
23 
 
 
[H2] Inhibition of fibrosis 
In the absence of effective therapy for NASH, being able to prevent the progression of fibrosis to 
cirrhosis would be advantageous. Even when effective NASH therapies are identified, there may be a 
role for short term use of effective antifibrotic agents to accelerate the reversal of fibrosis. No 
antifibrotic agents for liver disease are available but several are in RCTs including an anti-LOXL2 
antibody and a galectin binding molecule that have shown early promise. 
 
 
 
 Quality of life (QOL) in patients with NAFLD is understudied, though its importance is substantial 
and broadens our understanding of the overall burden of the disease (Box 3). Five studies have 
reported QOL scores in the context of NAFLD205–207. Overall findings have been similar and suggest 
that NAFLD is associated with a reduced overall, but predominately physical health-related (HR)-
QOL. Some data suggest that the impairment in QOL reported in patients with NAFLD may be 
beyond that reported in other aetiologies of liver disease205,206. In a sample of 771 patients with 
biopsy-confirmed NAFLD from the NASH clinical research network database, QOL as measured by 
the short form (SF)-36 questionnaire, was compared to a United States reference population with or 
without chronic disease208. In this study, impaired QOL was most evident in physical health with 
mental health affected to a lesser degree.  
Most patients with NAFLD are obese or overweight and even in those who are not, lifestyle change 
incorporating dietary modification and exercise are the cornerstone of therapy. Obesity has both 
health and psychosocial ramifications and can have a profound impact on an individual patient’s 
QOL. In this cross-sectional study, obesity was not associated with lower QOL per se208; however, the 
effects of imposing lifestyle change were not measured. One study evaluated the impact on weight 
loss on HR-QOL in patients with NAFLD and found that compared to those who did not lose weight, 
those that did, had improved HR-QOL scores over baseline values, comparable to the general 
population207. A prospective study of intensive lifestyle intervention illustrated that patients who lost 
>7% body weight benefitted not only from improvement or resolution in steatosis, 
necroinflammation and cellular ballooning (NASH resolution) but also fibrosis. 173 Importantly, no 
patient who lost more than 7% body weight had progression of fibrosis. In those that lost >10%, 
fibrosis improved in 81%, though overall numbers were small as was baseline extent of fibrosis. 
Weight loss and dietary change are hard to achieve and even harder to maintain, particularly in the 
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case of morbid obesity. Not only is behavioural change difficult in itself, but barriers — physical, 
social and economic (amongst others) — can pose a challenge to accomplishing them effectively.  
[H2] Bariatric surgery for NASH 
Compared to obese patients matched for co-morbidities, those that undergo bariatric surgery have 
decreased long-term mortality209–211. The largest impact on mortality comes from a reduction in 
myocardial infarction and malignancy; the two most common causes of death in patients with 
NAFLD. Bariatric surgery can be an effective and appropriate treatment strategy for a subset of 
patients with NAFLD, including those with advanced fibrosis and even carefully selected patients 
with compensated cirrhosis who meet criteria for bariatric surgery. 4,212. While it is important to note 
that bariatric surgery has not been studied prospectively specifically as a treatment for NASH, the 
best available data demonstrate that bariatric surgery in patients with NASH is safe and improves 
NASH-related liver disease, including fibrosis177. The liver-related benefits derived from bariatric 
surgery such as roux-en-Y gastric bypass or sleeve gastrectomy, extend beyond weight loss. Both 
procedures increase levels of GLP-1, which decreases appetite, slows gastric emptying and improves 
insulin sensitivity. Furthermore, GLP-1 effects modulate bile acid signalling, specifically through the 
farsenoid X receptor (FXR) which can alter the gut microbiome and can have other potential 
benefits. 213–215 
However, practitioners and patients are reluctant to pursue bariatric surgery, even when patients 
are appropriate candidates. Although there are known complications that vary according to the 
procedure performed, the overall the risk is low in properly selected patients216. Although carefully 
selected patients with established compensated (stable without significant abnormalities in liver 
function) cirrhosis can safely undergo bariatric surgery, cirrhosis is associated with a higher risk of 
post-operative complications including hepatic decompensation (development of ascites, hepatic 
encephalopathy or variceal bleeding)210. Careful patient selection can, therefore, not be 
overemphasized. Success of the intervention requires that patients remain committed to necessary 
lifestyle changes post-operatively to avoid regaining lost weight. More importantly, compliance with 
recommendations and follow-up are imperative to avoid metabolic and nutritional problems related 
to malabsorption or other consequences of bariatric surgery217.  
 
[H2] NASH and hepatocellular carcinoma  
Another consequence of liver disease in patients with NASH is HCC. The incidence of HCC is 
increasing both in the United States and worldwide. In Western countries, approximately 20% of 
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HCCs are found in patients with NASH-related liver disease; and even more if one includes HCCs 
occurring in the setting of cryptogenic cirrhosis, which often represents ‘burned out’ NASH that has 
lost its classic histological features218,219. A recent study in the United States based on Surveillance, 
Epidemiology, and End Results (SEER)-Medicare registries from 2004-2009 found NASH to be the 
underlying cause of HCC in 14.1% of nearly 5,000 cases, following alcoholic liver disease in 16% and 
hepatitis C in 54.9%. While this represented a 9% annual increase in NASH related HCC, NASH-HCC 
cases represented only 5% of liver transplants for HCC during the same time period, likely reflecting 
the burden of co-morbid illness in this population. Furthermore, patients with NASH and HCC were 
older and had shorter survival if they did not receive liver transplant compared to other aetiologies 
of liver disease220  
Wenzel and colleagues estimated the population attributable fraction (PAF), otherwise stated as the 
proportion of cases that can be attributed to specific risk factors, in patients with HCC from various 
causes of liver disease using the SEER-Medicare databases from 1994 to 2007221. Analysis of a cohort 
of 6,991 people showed that those with obesity and diabetes (presumably with NAFLD) had the 
highest PAF of HCC (36.6%) compared with other aetiologies, in descending order of magnitude – 
alcohol intake (23.5%), hepatitis C (22.4%), hepatitis B (6.3%) and other (3.2%). An important 
limitation of this study is that patients did not have a biopsy diagnosis of NAFLD or NASH. The PAF 
takes into account disease prevalence; thus, if NAFLD were to be eliminated, the impact on HCC 
would be substantial. However, the risk estimate of HCC in an individual patient with NAFLD is only 
in the order of 1.5-2.5 compared with 20.0-25.0 in a patient with hepatitis C. Per annum rates of HCC 
development in patients with NASH are lower than for patients with hepatitis C (2.6 vs. 4.0)21. 
Because NASH is so prevalent, it is not surprising that HCC as an indication for liver transplantation 
has increased 3.64 fold in patients with underlying NASH and a BMI>30 kg/m2. In comparison, HCC 
due to hepatitis C has increased only 2.25 fold over a 10-year period from 2002-2012. While diabetes 
and obesity are independent risk factors for HCC, the increase in NASH related HCC persisted after 
controlling for these variables222. Although older age, obesity, type 2 diabetes mellitus and male sex 
are risk factors for the development of HCC, NASH does seem to contribute independently221,223. 
Cirrhosis creates a milieu that is permissive for the development of HCC; thus, current screening 
recommendations focus primarily on cirrhotic patients. However, reports of HCC occurring in the 
absence of cirrhosis are on the rise, with some developing even in the absence of profound fibrosis. 
By some estimates, 10-75% of cases of HCC may occur in non-cirrhotic NAFLD224,225.  This is a serious 
problem because of the large number of patients affected by NAFLD and NASH at a population level. 
The individual risk of HCC in non-cirrhotic patients with NAFLD is even less well understood. 
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Consequently, although some individuals at risk for HCC may not be identified at an early stage of 
malignancy, there is presently insufficient evidence to alter current screening guidelines. Optimal 
recommendations for HCC screening in patients with NAFLD may change in the future as more is 
learned about individual risk in this challenging population. 
 
[H1] Outlook 
Both the short-term and long-term outlook for NAFLD will evolve as clinical and basic research 
continue to re-define the field (Box 4). NAFLD is an extremely complex and nuanced disease that 
represents the convergence of many pathways, risk factors and external influences that are not 
uniform in all patients. Therefore, it seems likely that NAFLD represents a constellation of various 
phenotypes that will require study from many angles as illustrated in this Primer. NAFLD is highly 
prevalent yet only a minor subset of patients progress to advanced liver disease, including HCC. 
Although many patients with NAFLD have a common metabolic profile (T2DM, hypertension, obesity 
amongst others) not all do. The underlying pathophysiology of NAFLD and in particular NASH is 
strongly linked to insulin resistance, aberrant hepatic lipid metabolism, visceral adiposity and 
inflammation. However several other important modulators of disease such as the environment and 
diet can further modify triggers of chronic extra- and intrahepatic immune pathways226, and the 
pathogenetic roles of gut dysbiosis227–229. The extent to which these factors drive disease progression 
and outcomes will be clarified as we gain further insight into the amassing data in this increasingly 
important area of research.  
Furthermore, differences in genetic susceptibility as well as epigenetics may help to better 
understand at risk populations. Therefore, a more in-depth evaluation of these differences will allow 
us to better understand the phenotypes of NAFLD. In turn, a more sophisticated ability to phenotype 
patients with NAFLD will further clarify differences in disease progression between patients and 
permit a more personalized approach to therapy.  
Animal models of disease have offered tremendous insight into relevant mechanisms, but to date, 
no animal model has faithfully replicated all aspects of the human condition. However this 
benchmark may not be compulsory or attainable given the heterogeneity of human disease.  
Just as the pathophysiology of NAFLD is not the same in all patients, treatment will need to be 
individualized. With rare exception, a commitment to lifestyle modification should be the foundation 
of any treatment plan, but this is not sufficient for most patients. In the morbidly obese or those 
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with severe co-morbid illness, bariatric surgery may have substantial benefit. Many patients will 
require more intense intervention – behavioural and pharmacological.  
Until recently the landscape of clinical trials for NASH was somewhat limited. Currently there are 
hundreds of clinical trials in NASH. The breadth of mechanisms being targeted reflects the 
complexity of the disease. As the field continues to advance and patients can be better classified by 
constellations of risk factors, or sub-classification using genomics or metabolomics, we will be able 
to offer a more personalized, mechanistically–derived treatment approach to each patient.  
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Box 2 | Grading and staging histological features of NAFLD and NASH 
 [H1] NAFLD Activity Score (NAS from 0-8)* 
 Steatosis (0 <5%; 1, 5-33%; 2, 33-66%; and 3, >66%) 
 Lobular inflammation, foci/20x magnification [Au:OK?] (0, not present;, 1= <2; 2, 2-4; and 3, 
>4) 
 Ballooning (0, not present; 1, few; 2, prominent ballooning) 
 [H1] Fibrosis score (0-4)* 
 1a: Delicate zone 3 perisinusoidal fibrosis (psf) ** 
 1b: Dense zone 3 psf** 
 1c: Portal [Au:OK?] only 
 2: Zone 3 + portal or periportal [Au:OK?]  
 3: Bridging (c-c, c-p, p-p) 
 4: Cirrhosis 
[H1] Fatty Liver Algorithm*** 
 Steatosis (0-3) 
 Activity (ballooning + lobular inflammation)  
o Ballooning is 0-2 
o Lobular Inflammation is 0-2 
 Fibrosis (similar to the fibrosis score of the NASH CRN above) 
* NIDDK NASH CRN: Pathology Committee NAFLD Scoring System for Clinical Trials230. Although the 
NAS is known to closely correlate with a diagnosis of NASH, it was created for clinical trials in order 
to assess change in the components and has been shown to be associated with liver tests, (ALT and 
AST)  while the pathologist's diagnosis associates with features of insulin resistance. The pathologist 
is encouraged to make a separate, pattern based diagnosis in addition to scoring the lesions 
**Delicate psf requires trichrome stain, whereas dense psf can be visualized on H&E stain first. ***A 
primary difference between the European algorithm and the CRN NAS is the former score was 
derived in order to equal a diagnosis. Steatosis > 1, activity > 2 (with both ballooning and lobular 
inflammation > 1) equals NASH.231 [Au: Reference here OK?]  
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Box 3. Affected quality of life aspects in NAFLD  
[H1] Physical health scores  
o People with NASH have poorer scores than patients with NAFLD 208 
o NAFLD as an aetiology may have lower HR-QOL scores compared to other 
aetiologies of liver disease205,206 
o Patients with cirrhosis have poorer scores than patients with no or any fibrosis205,206 
o Weight loss in people with NAFLD may improve QOL scores207 
[H1] Mental health scores205 
o Not affected by degree of necroinflammatory injury 
o Not affected by fibrosis stage or parenchymal remodelling (i.e. cirrhosis) 
[H1] Bariatric surgery 
o Improves overall survival in obesity173,207–210 
o Safe in patients with NASH 8Improves necroinflammatory disease, steatosis and 
fibrosis 
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Box 4. Clinical goals to diagnose and manage NAFLD 
[H1] Diagnosis 
 Validation of newer non-invasive detection methods to replace the use of invasive, 
expensive and imperfect ’gold standard‘ liver biopsy for detection and severity evaluation of 
NAFLD and NASH, including advanced fibrosis 
 Serum-based algorithms as markers for liver injury and fibrosis19,232–236  
 Imaging-based system to detect the constellation of lesions that collectively comprise NASH 
[Au:OK?]  
[H1] Management 
 Lifestyle intervention including management of meal content and portions and exercise 
programs 
 Therapeutic treatments based on a better understanding of the mechanisms of liver injury 
from the underlying and closely related links of overweight, obesity and insulin resistance 
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Figure 1: SNPs associated with NAFLD and NASH. [.];PNPLA3, adiponutrin;  and TM6F2,  
Figure 2. Mechanisms of steatosis and liver injury in NASH. (a) Hepatic fatty acids come from 3 
sources: diet, de novo lipogenesis (DNL) and adipose tissue lipolysis. Under normal circumstances, 
most fatty acids come from adipose tissue lipolysis. In people with fatty livers, the absolute amount 
of fatty acids from all sources increases, but the proportion coming from DNL increases considerably. 
Long-chain saturated fatty acids, which are the products of DNL, are cytotoxic to liver cells. 
Conversion of these fatty acids to triglyceride (TG) limits their toxicity. TG is what is visible as 
steatosis. (b) Fatty acids can kill hepatocytes by up-regulating the expression of death receptors and 
their ligands, culminating in death receptor activation (‘extrinsic’ cell death). Fatty acids can also 
cause ‘intrinsic’ cell death by inducing ER stress  leading to caspase-2-mediated cell death, in 
addition to JNK activation, production of reactive oxygen species (ROS) and mitochondrial 
dysfunction. In addition, fatty acids can stress mitochondria directly by creating high demand for 
beta-oxidation. This, too, can lead to excessive ROS production and mitochondrial dysfunction. 
Regardless of the pathway involved, fatty acid-induced cell death leads to the release of damage-
associated molecular patterns (DAMPs) into the extracellular space. (c) Hepatic inflammation in fatty 
livers involves resident and recruited macrophages. These cells express TLRs and inflammasomes, 
which respond to DAMPs released from dead hepatocytes as well as other compounds in the local 
milieu such as fatty acids and bacterial endotoxin from the intestine. Activation of these pathways 
stimulates the production of pro-inflammatory cytokines. Hepatic fibrosis in NASH is prompted by 
the activation of hepatic stellate cells to collagen-producing myofibroblasts. These cells express TLRs, 
and as such are responsive to DAMPs and endotoxin; they are also stimulated by cytokines released 
by inflammatory cells. They produce cytokines as well as collagen, which can prompt a vicious cycle 
of inflammation and further fibrosis.  
 
Figure 3: Overview of factors involved in the modulation of cellular epigenome.  
The figure depicts overall mechanisms involved in the modulation of cellular epigenome These 
epigenetic changes, which are technically regarded as chemical modifications of genomic DNA, 
include DNA methylation with methylation leading to gene silencing and demethylation to 
transcriptional activation and post-translational modifications of histones, such as methylation and 
acetylation. Together, they lead to changes in the chromatin structure that ultimately influence gene 
expression. Epigenetic alterations can be either transient or permanent; the mentioned epigenetic 
mechanisms are quite dynamic and can be reverted by therapeutic or lifestyle interventional 
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approaches. Epigenetic changes are shaped by both external and internal influences. For example, 
dietary components can influence activity of epigenetic modifications including histone 
acetyltransferases, histone deacetylases and histone and DNA methyltransferases. The cellular 
metabolic environment, including Intermediate metabolites and cofactors of the tricarboxylic acid 
(TCA) cycle, regulate the activity of enzymes involved in histone acetylation pathways and the 
balance between DNA methylation versus demethylation. Methylation of mtDNA by the DNA 
methyltransferase DNMT1 can contribute to the pathophysiology of complex diseases with 
mitochondrial dysfunction involvement, such as NAFLD.Finally, non-coding RNAs (including 
microRNAs (miRNAs) and long non-coding RNAs (LncRNAs)) can regulate transcription, methylation 
and chromatin structures  
 
Figure 4. Proposed diagnostic flow of NAFLD and NASH. NAFLD should be suspected if patients show 
several aspects of metabolic syndrome or a bright liver on ultrasonography. After excluding 
secondary causes of steatosis, non-invasive test (biomarkers, serum parameters and imaging), 
before converting to the ‘gold-standard’, that is liver biopsy. However, this is and invasive procedure 
and is suboptimal for screening and frequent monitoring. HCC, hepatocellular carcinoma; LFT, liver 
tests; MetS, metabolic syndrome; US, ultrasound. 
 
Figure 5: Diagnosis of liver fibrosis and NASH. [Au: Title added; OK?] A. Proton density fat fraction 
maps (PDFF), obtained by MRI, [Au:OK?] of an obese woman at multiple time points during a weight 
loss programme. PDFF is reported as a percentage, with a biological range in humans from 1% to 
~50%. Depending on the reference standard, a PDFF cut-off value of 3-6% differentiates non-
steatotic from steatotic liver. Notice progressive reduction in proton density fat fraction with 
reduction in body mass index (BMI). b-c| Same-day ultrasound-based shear wave elastography (b, 
US SWE) and MR elastography (c, MRE) in five adults with biopsy-proven NAFLD and fibrosis stages 
as shown. Notice that patients with greater fibrosis have greater US SWE-measured shear wave 
speed and greater MRE-measured stiffness (magnitude of complex shear modulus). 
 
Figure 6: Histological aspects of NAFLD and NASH. A| Marked steatosis without inflammation, 
hepatocyte injury (ballooning) or fibrosis. The steatosis is concentrated in acinar zone 3, the 
microcirculatory unit through which blood exits the liver around the terminal hepatic venule (in 
circle) and shows sparing of the periportal, zone 1 hepatocytes, the microcirculatory unit through 
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which portal and systemic blood enter and mix. This is the adult pattern of NAFLD. B| A closer view 
of a terminal hepatic venule (asterix) with hepatocytes around it with steatosis (clear vacuoles) and 
ballooning (arrows). Ballooned hepatocytes are commonly larger than neighboring hepatocytes due 
to swelling; the cytoplasm appears to be flocculent. Mallory-Denk bodies may occur in NASH, but are 
smaller than in alcoholic steatohepatitis. The inflammation is largely comprised of mononuclear cells 
including lymphocytes and macrophages. C| Perisinusoidal fibrosis in the perisinusoidal spaces of 
zone 3 is detected by trichrome staining, staining hepatocytes in red and fibrosis in blue. 
Hepatocytes with steatosis (S), ballooned hepatocytes (B) and pigmented Kupffer cells 
(macrophages, arrow) are indicated. [Au:OK?] D | NASH with bridging fibrosis (trichrome staining, 
blue), which typically surrounds and nearly encases individual hepatocytes. e| Cirrhotic NASH in 
which all lesions of active NASH remain present (steatosis (S), ballooning (B), inflammation (I), 
perisinuisoidal fibrosis (PSF)) f| NASH with cirrhosis, but no active lesions remain. One would only 
know this was a case of NASH-related cirrhosis by having had a prior biopsy with the diagnosis of 
active NASH. g| Paediatric pattern of NAFLD. In this very low power view of liver, it is apparent that 
the fat vacuoles localize near the portal tracts, and not the terminal hepatic venules. One involved 
portal area is encircled; a spared zone 3 is in a box. 
 
Figure 7. The lipotoxicity model of NASH and targets for therapy. Central to this understanding of 
the pathogenesis of NASH are free fatty acids, their sources in the hepatocyte and their fates. 
Delivery from adipose tissue and de novo lipogenesis (DNL) are the major sources of free fatty acids 
in hepatocytes. Mitochondrial beta-oxidation and secretion into the blood as triglyceride in very low 
density lipoprotein (VLDL) are the major fates. When the supply is excessive or the disposal is 
impaired (or most likely a combination of both), the generation of lipotoxic lipids can occur. This 
leads to hepatocellular injury, inflammation and the phenotype of NASH. These processes can be a 
stimulus for fibrogenesis and carcinogenesis. This paradigm predicts therapeutic targets (green 
dashed boxes) and targets (green), many of which are being exploited in clinical trials. 
 
 
 
 
Table 1. Epidemiology of NAFLD in adults 
Study* Country or region Setting Prevalence 
of NAFLD 
(%) 
Prevalence 
of NASH (%) 
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West     
Autopsy16 Canada Hospital autopsy 
record 
Non-obese:7  
Obese: 29** 
Mean: 6  
Non-obese: 
3  
Obese: 19 
**  
Histology17–19 United States, 
Europe, Australia 
Hospital liver 
biopsy series 
74–96 6-55 
Ultrasonography10–13 United States, 
Europe, Brazil 
General 
population or 
hospital clinics 
20–70 NR 
CT237 United States General 
population 
17 NR 
Proton-magnetic 
resonance 
spectroscopy14 
United States General 
population 
34 NR 
Asia, Africa and Pacific 
Islands 
    
Histology25,110,238,239 Korea, Malaysia, 
Hong Kong 
Liver donors and 
hospital liver 
biopsy series 
Liver donors: 
3 
Liver biopsy 
series: 100 
56–8% 
Ultrasonography240–243 Japan, China, Korea, 
India 
General 
population and 
hospital health 
checkup 
9–20 NR 
CT244,245 Saudi Arabia, Egypt Hospital patients 
and liver donors 
10–18 NR 
Proton-magnetic 
resonance 
spectroscopy25 
Hong Kong General 
population 
27 NR 
* When more than one reference is included, the data refer to a summary of several 
studies. ** BMI ≥30 kg/m2 ; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic 
steatohepatitis; NR, not reported. 
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Table 2. Epidemiology of paediatric and adolescent NAFLD 
Study 
 
Country n  Prevalence of 
NAFLD (%) 
Prevalence of 
NASH (%) 
Elevated ALT     
Strauss et al. 
2000246 
 
United States 2,450 16 N/A 
Zou et al. 2005247 
 
China 113 55.7* N/A 
Ultrasonography     
Guzzalonni et al. 
2000248 
 
Italy 375 38.7 N/A 
Fu et al. 2006249 
 
China 123 80.5  43.9 
Chan et al. 200435 
 
China 84 77 24 
Histology     
Schwimer et al. 
2003250 
 
United States 43 84* 
 
63 
Nobili et al. 
2006251 
 
Italy 84 80* 
 
26.2 
Feldstein et al. 
2009252  
 
United States 66 43 13.7 
Autopsy     
Schwimmer et al. 
200630 
  
United States 724 13 17.3 
*In overweight or obese populations. N/A, not available or not stated in the referenced 
articles; ALT, alanine aminotransferase.  
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